Last reviewed · How we verify
Postoperative infection — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| ALATROFLOXACIN | ALATROFLOXACIN | Pfizer | alatrofloxacin | 1997-01-01 | ||
| Ofloxacine | Ofloxacine | Assistance Publique - Hôpitaux de Paris | Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 4 drugs in Postoperative infection
- Assistance Publique - Hôpitaux de Paris · 1 drug in Postoperative infection
- Pfizer · 1 drug in Postoperative infection
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Postoperative infection:
- Postoperative infection treatment updates — RSS
- Postoperative infection treatment updates — Atom
- Postoperative infection treatment updates — JSON
Cite this brief
Drug Landscape (2026). Postoperative infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/postoperative-infection. Accessed 2026-06-10.
Related
- Postoperative infection full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing